adl-5859 and Drug-Related-Side-Effects-and-Adverse-Reactions

adl-5859 has been researched along with Drug-Related-Side-Effects-and-Adverse-Reactions* in 1 studies

Other Studies

1 other study(ies) available for adl-5859 and Drug-Related-Side-Effects-and-Adverse-Reactions

ArticleYear
Potent, orally bioavailable delta opioid receptor agonists for the treatment of pain: discovery of N,N-diethyl-4-(5-hydroxyspiro[chromene-2,4'-piperidine]-4-yl)benzamide (ADL5859).
    Journal of medicinal chemistry, 2008, Oct-09, Volume: 51, Issue:19

    Selective delta opioid receptor agonists are promising potential therapeutic agents for the treatment of various types of pain conditions. A spirocyclic derivative was identified as a promising hit through screening. Subsequent lead optimization identified compound 20 (ADL5859) as a potent, selective, and orally bioavailable delta agonist. Compound 20 was selected as a clinical candidate for the treatment of pain.

    Topics: Administration, Oral; Analgesics; Animals; Benzamides; Benzopyrans; Biological Availability; Dogs; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Ether-A-Go-Go Potassium Channels; Humans; Maximum Tolerated Dose; Mice; Molecular Structure; Motor Activity; Pain; Pain Measurement; Rats; Receptors, Opioid, delta; Toxicity Tests

2008